91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Digital health technologies are rapidly becoming essential to clinical trial strategies as regulators and sponsors embrace them to streamline operations, reduce patient burden, and generate higher?quality real?world data.
-
In this PharmaTimes article, Nagalakshmi Shetty explores how clinical data science is evolving from traditional management toward intelligent, risk-based, patient-centric research frameworks.
-
Despite the increasing use of AI in medical devices and software as medical devices (SaMD), global regulatory authorities are playing catch up to develop appropriate submission channels.
Read the article in Med-Tech Insights.
-
Every clinical trial has challenges, but trials researching SaMD use to treat mental health disorders have unique ethical, regulatory and technical ones. In this Applied Clinical Trials article 91黑料’s Devin Ridgley and JoAnne Bronikowski explore the implications of a vulnerable patient population and new technology.
-
This article by Greg Licholai discusses how AI is revolutionising drug discovery, with companies like Lila Sciences and Recursion Pharmaceuticals leading the charge by using AI to accelerate scientific breakthroughs. Lila focuses on creating "scientific superintelligence" through autonomous labs, while Recursion maps human biology to discover new treatments faster.
-
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
-
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce operational efficiencies. AI-powered digital measures are being developed and validated to better define disease, patients, and drug efficacy.
-
In the Irish Times Life Sciences and Stem supplement, 91黑料’s CIO Tom O’Leary discussed AI is transforming drug development across a range of specific use cases, from discovery to clinical trials and post-marketing.
-
This news piece from Clinical Trials Arena provides an overview of the findings of 91黑料’s recent Digital Disruption survey, which found sentiment towards artificial intelligence and digital tools in the clinical research sector is positive.
-
In this interview with Asia Business Outlook Magazine, Nagalakshmi Shetty, Vice President & India Country Head shares how changes in data management have changed the way clinical research is practiced and emphasises the role of interdisciplinary collaborations in progressing research.
